Company

Cancer is a global challenge, impacting lives and families in countless ways.

Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high resolution, real-time, advanced imaging tools that address unmet medical needs. A Toronto-based company established in 2013, with U.S. headquarters in Dallas, Texas, Perimeter seeks to harness the power of big data, artificial intelligence, and machine learning technology to further its mission of improving the standard of care, providing better long-term outcomes for patients, and reducing healthcare costs.

Perimeter envisions a world where patients no longer experience the emotional and physical trauma of a second operation due to cancer left behind.

The Re-Excision Challenge

Surgeons have worked tirelessly to solve for intraoperative margin assessment, with the ultimate goal of improving survivability and quality of life. Yet, it still remains one of their most pressing problems, recognized by professional societies as the “re-excision epidemic.”

If margins are positive, patients typically return for another surgery, impacting them physically, emotionally and financially, delaying adjunct treatments and getting back to their lives.

Even for skilled surgeons using the latest techniques, the odds of needing a repeat surgery are relatively high—nearly 1 in 4 for some types of cancer:

23% of breast lumpectomies require re-excision4
11.5% of thyroid cancers have a positive margin5
21% of prostate cancers have a positive margin5

It’s All About Managing Margins

Surgeons will do everything they can to achieve clean margins but they cannot detect remaining cancer cells—especially with hard-to-detect cancers—by sight or touch.

Traditional imaging used in the operating room, such as X-ray, does not have the resolution needed to detect microscopic cancer cells, and Pathology must be used to confirm clean margins, which takes up to a week.

A Game Changer for Margin Management

Perimeter’s proprietary Optical Coherence Tomography (OCT) technology provides high-definition, 3d images of margins in the operating room. This has the potential to give surgeons clarity on margin status so they can take more tissue at the point of care, not days later when pathology reports come back.

Optical Coherence Tomography (OCT), developed out of MIT in 1991, can give surgeons the resolution to help visualize hard-to-detect tissue microstructures associated with early-stage cancers.

Simply put, we provide advanced margin imaging in the moment – when it matters most.

What Drives Us

Learn More About Our AI Technology

*Perimeter B-Series OCT with ImgAssist AI is not available for sale in the United States.
CAUTION: Investigational Device. Limited by U.S. law to investigational use.

What Drives Us

Driven to transform
cancer surgery

Cancer is a global challenge, and we envision a world where patients no longer experience the costly emotional and physical trauma of being called back for a second surgery due to cancer left behind.

Innovating the medical
imaging paradigm

With a clarity surgeons have never seen before, we seek to revolutionize medical imaging — creating innovative new products and groundbreaking technologies that are synonymous with excellence and widely recognized as the new standard of care.

Tapping the power of
Artificial Intelligence (AI)

Our data analytics and machine learning software works behind the scenes to optimize and accelerate surgeons’ decision making in the operating room. We provide the insight needed at the point of care, when it matters most.

Learn More About Our AI Technology

*Perimeter B-Series OCT with ImgAssist AI is not available for sale in the United States.
CAUTION: Investigational Device. Limited by U.S. law to investigational use.

Why We Started Perimeter

The re-excision problem faced by surgeons and patients
Clinical Paper
Alpha beta hypotheses vesting period iteration A/B testing customer value proposition startup.
Clinical Paper
Alpha beta hypotheses vesting period iteration A/B testing customer value proposition startup.
Clinical Paper
Alpha beta hypotheses vesting period iteration A/B testing customer value proposition startup.

View All Resources

You Might Be Interested In

Leadership Team

Careers

News & Events

Connect with Us

Get in Touch